文献速递妇科

女性等待I型子宫内膜癌手术期间,长效醋酸甲羟孕酮减少肿瘤腺体细胞密度

While women await surgery for type I endometrial cancer, depot medroxyprogesterone acetate reduces tumor glandular cellularity.
PubMed 文献 · Am J Obstet Gynecol · 2018-07-29

这项双盲随机对照试验将76例因子宫内膜上皮内瘤变或I型子宫内膜癌等待子宫切除术的患者随机分为术前长效醋酸甲羟孕酮400mg注射组与0.9%生理盐水注射组,发现长效醋酸甲羟孕酮组肿瘤腺体细胞密度下降幅度大于安慰剂组,两组生活质量无显著差异。

要点

  • 长效醋酸甲羟孕酮组肿瘤腺体细胞密度平均变化为-64(-31.8%)个细胞/每四分之一高倍视野,安慰剂组为-14(-5.5%)个细胞/每四分之一高倍视野,P=.002。
  • 该效应在等待手术≥3周的女性中最为明显。
  • 两组在癌症治疗功能评估-子宫内膜调查(第4版)的生活质量评分上无显著差异。

核心结论

  • 术前给予长效醋酸甲羟孕酮对I型子宫内膜癌产生的肿瘤效应大于安慰剂注射。
  • 长效醋酸甲羟孕酮注射可被患者接受且耐受良好。
  • 作者认为长效醋酸甲羟孕酮可能成为预计等待手术时间较长的女性有意义的术前过渡治疗。

研究设计与样本

  • 双盲随机对照试验,在术前访视时注射长效醋酸甲羟孕酮400mg或0.9%生理盐水。
  • 近期使用过孕激素类似物的患者被排除。
  • 计算样本量76例(每组38例),以检测两组间腺体细胞密度下降20%的差异。
  • 主要结局肿瘤腺体细胞密度由2名专职妇科病理学家审阅诊断活检并与治疗后子宫切除标本比较。
  • 2015年3月至2016年3月期间筛查148名女性,入组76例,38例随机接受长效醋酸甲羟孕酮注射,38例随机接受安慰剂注射。

主要发现

  • 长效醋酸甲羟孕酮组肿瘤腺体细胞密度平均变化为-64(-31.8%)个细胞/每四分之一高倍视野,安慰剂组为-14(-5.5%)个细胞/每四分之一高倍视野,P=.002。
  • 该效应在等待手术≥3周的女性中最为明显。
  • 长效醋酸甲羟孕酮组中若干额外的肿瘤分化和细胞增殖减少的组织学及免疫组化标志物较安慰剂组更明显。
  • 两组在癌症治疗功能评估-子宫内膜调查(第4版)的生活质量上无显著差异。
  • 仅5.3%被接触的患者因对肌肉注射的担忧而拒绝参与。

临床怎么用

  • 作者认为长效醋酸甲羟孕酮可能成为预计等待手术时间较长的女性有意义的术前过渡治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple population-level studies have demonstrated an adverse effect of long wait times to surgery on survival for women with endometrial cancer. Other retrospective and nonrandomized prospective studies have shown that preoperative administration of depot medroxyprogesterone acetate decreases tumor glandular cellularity, which may be a surrogate marker for clinically meaningful tumor response. OBJECTIVE: We sought to determine whether preoperative injection with depot medroxyprogesterone acetate decreases tumor glandular cellularity when compared to placebo injection in women awaiting hysterectomy for endometrial intraepithelial neoplasia or type I endometrial cancer, and to determine whether depot medroxyprogesterone acetate injection affects quality of life while waiting for surgery. STUDY DESIGN: This was a double-blind, randomized controlled trial of 400-mg depot medroxyprogesterone acetate injection or 0.9% saline injection at the preoperative visit. Patients with recent use of progesterone analogs were excluded. A sample size of 76 patients (38 per arm) was calculated to detect a 20% difference in decreased glandular cellularity between arms. Pathologic characteristics including the primary outcome, tumor glandular cellularity, from patients' diagnostic biopsies were reviewed by 2 dedicated gynecologic pathologists and compared to posttreatment hysterectomy specimens. On the night prior to surgery, patients completed the Functional Assessment of Cancer Therapy-Endometrial Survey (Version 4) to report quality of life while waiting for surgery. In comparing characteristics between the intervention and control groups, t tests were used for continuous variables, and χ2 or Fisher exact tests were used where appropriate for categorical data. RESULTS: From March 2015 through March 2016, 148 women were screened and 76 patients were enrolled. In all, 38 patients were randomized to and received depot medroxyprogesterone acetate injection and 38 were randomized to and received placebo injection. Demographics were similar between groups. Patients who received depot medroxyprogesterone acetate injection experienced a larger decrease in tumor glandular cellularity (mean change -64 [-31.8%] vs -14 [-5.5%] cells per quarter high-powered field in depot medroxyprogesterone acetate vs placebo groups, P = .002). This effect was most pronounced in women waiting ≥3 weeks for surgery. Several additional histologic and immunohistochemical markers of tumor differentiation and decreased cell proliferation were more pronounced in the depot medroxyprogesterone acetate group than in the placebo group. There were no significant differences in quality of life between groups on the Functional Assessment of Cancer Therapy-Endometrial Survey. Only 5.3% of patients who were approached declined to participate due to concerns regarding an intramuscular injection. CONCLUSION: Administration of depot medroxyprogesterone acetate prior to surgery for type I endometrial cancers caused greater tumor effect than placebo injection. Injection of depot medroxyprogesterone acetate was acceptable to and well tolerated by patients. Depot medroxyprogesterone acetate may represent a meaningful bridge to surgery in women who can expect long wait times.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Fiascone S, Danilack VA, Kao MJ, et al. While women await surgery for type I endometrial cancer, depot medroxyprogesterone acetate reduces tumor glandular cellularity. Am J Obstet Gynecol. 2018. PMID: 30063901. doi:10.1016/j.ajog.2018.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。